Trial Profile
Effects of Multiple Baricitinib (LY3009104) Doses on the Pharmacokinetics of a Cytochrome P450 3A Substrate, Simvastatin, in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Simvastatin
- Indications Cystic fibrosis; Diabetic cardiomyopathy; Diabetic nephropathies; Hypercholesterolaemia; Low HDL cholesterol; Psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 08 Jan 2014 Status changed from no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Oct 2013 New trial record